<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01964755</url>
  </required_header>
  <id_info>
    <org_study_id>20090166</org_study_id>
    <nct_id>NCT01964755</nct_id>
  </id_info>
  <brief_title>Chemotherapy for Relapsed Epstein Barr Virus Associated Lymphoma</brief_title>
  <official_title>Phase II Study of Chemotherapy (Doxorubicin, Methotrexate and Leucovorin) in Combination With Antiviral-Based Therapy (Zidovudine + Hydroxyurea) for AIDS, Immunocompromised, or Immunocompetent Patients With Relapsed or CNS Positive Epstein Barr Virus Associated Lymphoma</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Miami</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University of Miami</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      By combining a variety of agents that potentiate Zidovudine (ZDV), the investigators hope to
      induce remission in this generally fatal disease. Most therapies for aggressive B cell
      lymphomas are based upon intensive chemotherapeutic regimens, expensive modalities (bone
      marrow transplant, Rituximab), or experimental approaches (gene therapy, cytotoxic T cell
      infusion) that are difficult to implement in heavily pre-treated patients. Therapy for
      relapsed aggressive B cell lymphomas is very poor. Even curable lymphomas such as Burkitt
      Lymphoma (BL) and Hodgkin lymphoma are extremely difficult to treat in relapse and/or after
      stem cell transplant failure. The investigators propose a novel therapeutic approach that
      exploits the presence of Epstein-Barr virus (EBV) in lymphomas; antiviral mediated
      suppression of NF-kB and disruption of viral latency.
    </textblock>
  </brief_summary>
  <overall_status>Terminated</overall_status>
  <why_stopped>
    Investigator Decision
  </why_stopped>
  <start_date type="Actual">April 21, 2009</start_date>
  <completion_date type="Actual">June 7, 2018</completion_date>
  <primary_completion_date type="Actual">June 7, 2018</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Rate of Complete Response to Protocol Therapy</measure>
    <time_frame>About 21 days</time_frame>
    <description>Complete Response (CR) rate in study participants to protocol therapy. Response will be assessed via CT Scan and bone marrow aspirate/biopsy, if applicable. Complete response criteria include:
Complete disappearance of all detectable clinical and radiographic evidence of disease and disappearance of all disease-related symptoms if present before therapy, and normalization of those biochemical abnormalities definitely assignable to Non Hodgkin's Lymphoma (NHL);
All lymph nodes and tumor masses disappeared or regressed to normal size (≤ 1.5 cm in their greatest transverse diameters for nodes &gt; 1.5 cm before therapy);
Previously involved nodes that were 1.1 to 1.5 cm in their greatest transverse diameter (GTD) before treatment must have decreased to ≤ 1 cm in their GTD after treatment, or by more than 75% bin the sum of the products of the greatest diameters (SPD);
No new sites of disease.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>One-year Rate of Overall Survival</measure>
    <time_frame>12 months</time_frame>
    <description>Rate of overall survival of study participants at one year since initiation of protocol therapy. Overall survival (OS) will be measured from the date of initiation of study treatment until date of death from any cause. In the absence of death, the follow-up will be censored at date of last contact (censored observation). Kaplan-Meier estimate of overall survival at one-year.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>One-Year Rate of Failure-Free Survival (FFS)</measure>
    <time_frame>12 months</time_frame>
    <description>Rate of failure-free survival of study participants one-year after start of protocol therapy. Failure-free survival (FFS) will be measured from the date of treatment initiation until date of documented disease progression, relapse after response, or death from any cause. For patients alive and free of relapse or progression, follow-up time will be censored at the last documented date of failure-free status. Kaplan-Meier estimate of failure-free survival at one-year.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Rate of Toxicity Related to Protocol Therapy</measure>
    <time_frame>Through Duration of Protocol Therapy, Up to six 21-day cycles (+/- 7 days)</time_frame>
    <description>Rate of adverse events, serious adverse events or other toxicities related to protocol therapy in study participants.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>HIV Viral Load in Positive Subjects Before, During and After Protocol Therapy</measure>
    <time_frame>From Baseline Up to 1 Year Post-Therapy</time_frame>
    <description>Measurement of HIV Viral Load in positive subjects before, during and after protocol therapy to assess the effect of protocol therapy on immune reconstitution or exhaustion.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>T-Cell Subset Levels in Peripheral Blood in Positive Participants Before, During and After Protocol Therapy</measure>
    <time_frame>From Baseline Up to 1 Year Post-Therapy</time_frame>
    <description>Measurement of T-cell subset levels (CD4, CD8) in peripheral blood before, during and after protocol therapy to assess the effect of protocol therapy on immune re-constitution or exhaustion.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>EBV Viral Load in Peripheral Blood Before, During and After Protocol Therapy</measure>
    <time_frame>From Baseline Up to 1 year Post-Therapy</time_frame>
    <description>Measurement of Epstein Barr Virus (EBV) viral load in peripheral blood in study participants before, after treatment, and during surveillance in order to correlate the presence of with tumor load and disease status.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>EBV Reactivation in Circulating Peripheral Blood Memory B-cells Before and After Protocol Therapy.</measure>
    <time_frame>From Baseline Up to 1 year Post-Therapy</time_frame>
    <description>Measurement of EBV reactivation in circulating peripheral blood memory B-cells before and after treatment with chemotherapy/Zidovudine (ZDV) in order to assess the drug effect on EBV latency.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Baseline Tumor EBV Gene Expression Profile in Study Participants</measure>
    <time_frame>Baseline</time_frame>
    <description>Determine baseline tumor EBV gene expression profile to assess viral thymidine kinases. (BXLF1/vTK and BGLF4/PK), EBV latency pattern (I, II or III) and lytic phase.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Measurement of Immune Activation Markers and Inflammation in Peripheral Blood</measure>
    <time_frame>Through Duration of Response to Protocol Therapy Until Disease Progression, Up to 5 years</time_frame>
    <description>Measurement of immune activation markers and inflammation in peripheral blood in response to treatment and EBV reactivation.</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">6</enrollment>
  <condition>Epstein Barr Virus Associated Non Hodgkin's Lymphoma</condition>
  <condition>Epstein Barr Virus Associated Hodgkin's Lymphoma</condition>
  <condition>Post-Transplant Lymphoproliferative Disease</condition>
  <arm_group>
    <arm_group_label>Chemotherapy + Antiviral-Based Therapy</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Combination Chemotherapy for up to six (6) 21-day cycles and Antiviral-Based Therapy:
Chemotherapy: Up to 6 cycles, 21 days each:
Doxorubicin: 20 mg/m2 intravenously (IV) on Day 1 per study protocol;
Rituximab: 375mg/m2 (optional) IV on Day 1 per study protocol;
Methotrexate: 3.5 gm/m2 IV on Day 2 per study protocol;
Leucovorin: 10 mg/m2 IV starting approximately 24 hours after start of Methotrexate infusion, and then 25 mg orally every 6 hours for at least 10 doses per study protocol;
Antiviral-Based Therapy
Zidovudine: Starting 750 mg/m2 IV on Day 2, then 1200 mg orally twice daily for 10 doses per study protocol;
Hydroxyurea: 1,000 mg orally twice daily starting Day 2 for a total of 10 doses per study protocol.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Doxorubicin</intervention_name>
    <description>Doxorubicin 20 mg/m2 intravenously will be administered on Day 1 in patients with systemic (non-primary CNS) lymphoma as per institutional guidelines</description>
    <arm_group_label>Chemotherapy + Antiviral-Based Therapy</arm_group_label>
    <other_name>Adriamycin</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Methotrexate</intervention_name>
    <description>Methotrexate administered starting on Day 2, per study protocol.</description>
    <arm_group_label>Chemotherapy + Antiviral-Based Therapy</arm_group_label>
    <other_name>Methotrexate sodium</other_name>
    <other_name>Mexate</other_name>
    <other_name>Mexate-aq</other_name>
    <other_name>Folex</other_name>
    <other_name>Abitrexate</other_name>
    <other_name>Rheumatrex</other_name>
    <other_name>Amethopterin</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Leucovorin</intervention_name>
    <description>Leucovorin administered first intravenously 24 hours after start of Methotrexate infusion, then orally every 6 hours for at least 10 doses, per study protocol.</description>
    <arm_group_label>Chemotherapy + Antiviral-Based Therapy</arm_group_label>
    <other_name>Leucovorin Calcium</other_name>
    <other_name>Wellcovorin</other_name>
    <other_name>Citrovorum Factor</other_name>
    <other_name>Folinic Acid</other_name>
    <other_name>5-formyl tetrahydrofolate</other_name>
    <other_name>LV</other_name>
    <other_name>LCV</other_name>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Hydroxyurea</intervention_name>
    <description>Hydroxyurea administered orally twice daily starting on Day 2, and continuing for a total of 10 doses, per study protocol</description>
    <arm_group_label>Chemotherapy + Antiviral-Based Therapy</arm_group_label>
    <other_name>Hydroxycarbamide (rINN)</other_name>
    <other_name>Hydrea</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Zidovudine</intervention_name>
    <description>Zidovudine administered first intravenously on Day 2, and then orally twice daily for 10 doses, per study protocol.</description>
    <arm_group_label>Chemotherapy + Antiviral-Based Therapy</arm_group_label>
    <other_name>Retrovir</other_name>
    <other_name>Azidothymidine (AZT)</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Rituximab</intervention_name>
    <description>Rituximab is optional and will be administered to study participants, per study protocol.</description>
    <arm_group_label>Chemotherapy + Antiviral-Based Therapy</arm_group_label>
    <other_name>Rituxan</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Any stage, histologically or cytologically documented intermediate to high grade
             relapsed or refractory EBV+ non-Hodgkin's (NHL) or Hodgkin's lymphoma (HL), or any
             treated or untreated patients with EBV+ lymphoma involving CNS. Patients with relapsed
             or refractory monomorphic (monoclonal) post-transplant lymphoproliferative disease
             (PTLD) are also eligible.

          2. Patients who are HIV+ or negative. Documentation of HIV infection can be done at any
             time prior to study entry. Documentation may be serologic (positive ELISA and positive
             Western blot), molecular (positive HIV viral RNA), or other federally approved
             licensed HIV test. Prior documentation of HIV seropositivity is acceptable.

          3. Tumors must be positive for EBV. This may be done either by Epstein-Barr virus-encoded
             small RNA (EBER) stain on the original tumor or the biopsy of relapsed disease (if
             performed). Biopsy of relapsed disease is desirable but not mandatory. If stains for
             Epstein-Barr virus latent membrane protein 1 (LMP1) done outside are positive, EBER
             does not need to be done.

          4. All patients, except those who have CNS involvement, must have relapsed or progressed
             from at least one previous chemotherapy based regimen.

          5. Measurable or non-measurable tumor parameter(s). Non-measurable tumor parameter(s) is
             defined as not having bi-dimensional measurements (e.g., gastric or marrow
             involvement), but can be followed for response by other diagnostic tests such as
             gallium scan, Positron emission tomography (PET) imaging and/or bone marrow biopsy.

          6. Age ≥ 18 years.

          7. Karnofsky performance status (KPS) ≥ 50%/Eastern Cooperative Oncology Group (ECOG)
             Performance Score 0, 1, 2.

          8. Patients must have adequate end organ and bone marrow function as defined below:

               -  8.1 Absolute neutrophil count ≥ 1,500 cells/mm3 and platelets ≥ 75,000 cells/dL
                  unless cytopenias are secondary to lymphomatous involvement of bone marrow or due
                  to HIV-related thrombocytopenia. All patients must be off colony stimulating
                  factor therapy at least 24 hours prior to institution of Cycle 1 chemotherapy.

               -  8.2 Adequate hepatic function: Serum glutamic-oxaloacetic transaminase (SGOT) ≤ 5
                  times the upper limit of normal. Total bilirubin ≤ 2.0 mg/dL (unless elevated
                  secondary to lymphomatous involvement of liver or biliary system or due to other
                  HIV medications [e.g., indinavir, tenofovir or atazanavir]). Patients who are
                  negative for Hepatitis B, or if infected with Hepatitis B, receiving
                  anti-Hepatitis B therapy are eligible. All subjects will be required to be
                  screened for Hepatitis B and C. Per Infectious Diseases Society of America (IDSA)
                  and American Association for the Study of Liver Diseases (AASD) guidelines, those
                  subjects that show no immunity, defined by the lack of Hepatitis B surface
                  antibody, and show evidence of chronic infection (i.e. HBsAg+, HBcore+, HBsAB-)
                  will be required to be on anti-Hepatitis B therapy, during the study, in order to
                  be eligible. Patients will be permitted to enroll in the study provided liver
                  function tests meet criteria listed above, and there is no evidence of cirrhosis.
                  The exact Hepatitis B therapy will be at the discretion of the infection disease
                  specialist or investigator. However all patients who present with acute hepatitis
                  B or show normal transaminases and are HBsAg+ and IgM+ for Hepatitis core antigen
                  will not be eligible for trial enrollment. Subjects who are Hepatitis C antibody
                  positive, with or without a positive Hepatitis C RNA level, will be permitted to
                  enroll in the study provided liver function tests meet criteria listed above, and
                  have no evidence of cirrhosis. Patients diagnosed with Hepatitis C less than 6
                  months from trial enrollment, will be considered to have Acute Hepatitis C and
                  will be excluded from study unless Hep C viral load is undetectable.

               -  8.3 Creatinine ≤ 2.0 mg/dL or creatinine clearance ≥ 60 mL/min unless due to
                  renal involvement by lymphoma.

          9. Concurrent radiation, with or without steroids, for emergency conditions secondary to
             lymphoma (CNS tumor, cord compression, etc.) will be permitted.

         10. Females with childbearing potential must have a negative serum pregnancy test within 7
             days prior of entering into the study. Men and women must agree to use adequate birth
             control if conception is possible during the study. Women must avoid pregnancy and men
             avoid fathering children while in the study and for 6 months following the last study
             drug treatment.

         11. Able to give consent.

         12. Patients already receiving erythropoietin or Granulocyte-colony stimulating factor
             (G-CSF) are eligible, although G-CSF therapy must be discontinued at least 24 hours
             prior to receiving chemotherapy.

         13. The maximum cumulative dose of doxorubicin allowed is 450 mg/m2. Patients who have
             previously received doxorubicin with a cumulative dose of 350 mg/m2 or greater are
             eligible but MAY NOT receive doxorubicin under protocol.

        Exclusion Criteria:

          1. Concurrent active malignancies, with the exception of in situ carcinoma of the cervix,
             non-metastatic, non-melanomatous skin cancer, or Kaposi sarcoma not requiring systemic
             chemotherapy.

          2. Myocardial infarction (MI) within 6 months prior to study entry, New York Heart
             Association (NYHA) Class II or greater heart failure, uncontrolled angina, severe,
             uncontrolled ventricular arrhythmias, clinically significant pericardial disease, or
             electrocardiograph evidence of acute ischemic or active conduction system
             abnormalities.

          3. Left Ventricular Ejection Fraction (LVEF) that is less than the lower institutional
             limits of normal as assessed by Multiple Gated Acquisition (MUGA) scan or
             echocardiogram within 6 weeks prior to registration.

          4. Subjects with viral hepatitis who do not meet the criteria listed on (8.2) will be not
             be eligible. All patients who present with acute hepatitis B including those with
             normal transaminases who are HBsAg+ and IgM + for hepatitis core antigen will not be
             eligible. Subjects who are Hepatitis B core antibody positive are eligible only if
             they start or are on prophylactic therapy. A hepatitis B viral load should be
             confirmed negative on all patients who are hepatitis B core antibody positive, but
             hepatitis B antigen negative. Patients refusing to take any anti-hepatitis B therapy
             during study will also be excluded. Patients diagnosed with Hepatitis C are eligible
             if they meet criteria listed on (8.2).

          5. Psychological, familial, sociological or geographical conditions that do not permit
             treatment and/or medical follow-up required to comply with the study protocol.

          6. Patients may not be receiving any other investigational agents.

          7. Uncontrolled intercurrent illness including, but not limited to, ongoing or active
             infection, symptomatic congestive heart failure, unstable angina pectoris, cardiac
             arrhythmia, or psychiatric illness/social situations that would limit compliance with
             study requirements. Patients with mycobacterium avium will not be excluded.

          8. Pregnant or breast-feeding women.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Juan Carlos Ramos, MD</last_name>
    <role>Study Chair</role>
    <affiliation>University of Miami</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>University of Miami</name>
      <address>
        <city>Miami</city>
        <state>Florida</state>
        <zip>33136</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of North Carolina at Chapel Hill</name>
      <address>
        <city>Chapel Hill</city>
        <state>North Carolina</state>
        <zip>27999</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>August 2019</verification_date>
  <study_first_submitted>October 14, 2013</study_first_submitted>
  <study_first_submitted_qc>October 14, 2013</study_first_submitted_qc>
  <study_first_posted type="Estimate">October 17, 2013</study_first_posted>
  <results_first_submitted>May 6, 2019</results_first_submitted>
  <results_first_submitted_qc>August 23, 2019</results_first_submitted_qc>
  <results_first_posted type="Actual">September 23, 2019</results_first_posted>
  <last_update_submitted>August 23, 2019</last_update_submitted>
  <last_update_submitted_qc>August 23, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">September 23, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>University of Miami</investigator_affiliation>
    <investigator_full_name>Juan C. Ramos</investigator_full_name>
    <investigator_title>Associate Professor of Clinical</investigator_title>
  </responsible_party>
  <keyword>EBV+</keyword>
  <keyword>NHL</keyword>
  <keyword>HL</keyword>
  <keyword>Non Hodgkin's Lymphoma</keyword>
  <keyword>Hodgkin's Lymphoma</keyword>
  <keyword>Epstein Barr Virus</keyword>
  <keyword>Epstein Barr Virus Associated Non Hodgkin's Lymphoma</keyword>
  <keyword>Epstein Barr Virus Associated Hodgkin's Lymphoma</keyword>
  <keyword>Post-Transplant Lymphoproliferative Disease</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lymphoma</mesh_term>
    <mesh_term>Lymphoma, Non-Hodgkin</mesh_term>
    <mesh_term>Hodgkin Disease</mesh_term>
    <mesh_term>Lymphoproliferative Disorders</mesh_term>
    <mesh_term>Virus Diseases</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Leucovorin</mesh_term>
    <mesh_term>Tetrahydrofolates</mesh_term>
    <mesh_term>Formyltetrahydrofolates</mesh_term>
    <mesh_term>Zidovudine</mesh_term>
    <mesh_term>Rituximab</mesh_term>
    <mesh_term>Doxorubicin</mesh_term>
    <mesh_term>Methotrexate</mesh_term>
    <mesh_term>Hydroxyurea</mesh_term>
    <mesh_term>Levoleucovorin</mesh_term>
  </intervention_browse>
  <provided_document_section>
    <provided_document>
      <document_type>Study Protocol and Statistical Analysis Plan</document_type>
      <document_has_protocol>Yes</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>Yes</document_has_sap>
      <document_date>September 27, 2016</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/55/NCT01964755/Prot_SAP_000.pdf</document_url>
    </provided_document>
  </provided_document_section>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Chemotherapy + Antiviral-Based Therapy</title>
          <description>Combination Chemotherapy for up to six (6) 21-day cycles and Antiviral-Based Therapy per study protocol:
Chemotherapy: Up to 6 cycles, 21 days each:
Doxorubicin: 20 mg/m2 intravenously (IV) on Day 1;
Rituximab: 375mg/m2 (optional) IV on Day 1;
Methotrexate: 3.5 gm/m2 IV on Day 2;
Leucovorin: 10 mg/m2 IV starting approximately 24 hours after start of Methotrexate infusion, and then 25 mg orally every 6 hours for at least 10 doses;
Antiviral-Based Therapy
Zidovudine: Starting 750 mg/m2 IV on Day 2, then 1200 mg orally twice daily for 10 doses;
Hydroxyurea: 1,000 mg orally twice daily starting Day 2 for a total of 10 doses.
Doxorubicin: Doxorubicin 20 mg/m2 intravenously will be administered on Day 1 in patients with systemic (non-primary CNS) lymphoma as per institutional guidelines
Methotrexate: Methotrexate administered starting on Day 2.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="6"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>Cycle 2</title>
              <participants_list>
                <participants group_id="P1" count="5"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>Cycle 3</title>
              <participants_list>
                <participants group_id="P1" count="4"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>Cycle 4</title>
              <participants_list>
                <participants group_id="P1" count="4"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>Cycle 5</title>
              <participants_list>
                <participants group_id="P1" count="4"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="4"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Death</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Chemotherapy + Antiviral-Based Therapy</title>
          <description>Combination Chemotherapy for up to six (6) 21-day cycles and Antiviral-Based Therapy per study protocol:
Chemotherapy: Up to 6 cycles, 21 days each:
Doxorubicin: 20 mg/m2 intravenously (IV) on Day 1;
Rituximab: 375mg/m2 (optional) IV on Day 1;
Methotrexate: 3.5 gm/m2 IV on Day 2;
Leucovorin: 10 mg/m2 IV starting approximately 24 hours after start of Methotrexate infusion, and then 25 mg orally every 6 hours for at least 10 doses;
Antiviral-Based Therapy
Zidovudine: Starting 750 mg/m2 IV on Day 2, then 1200 mg orally twice daily for 10 doses;
Hydroxyurea: 1,000 mg orally twice daily starting Day 2 for a total of 10 doses.
Doxorubicin: Doxorubicin 20 mg/m2 intravenously will be administered on Day 1 in patients with systemic (non-primary CNS) lymphoma as per institutional guidelines
Methotrexate: Methotrexate administered starting on Day 2.</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="6"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>&lt;=18 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Between 18 and 65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="5"/>
                  </measurement_list>
                </category>
                <category>
                  <title>&gt;=65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Median</param>
          <dispersion>Full Range</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="47" lower_limit="33" upper_limit="65"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Ethnicity (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Hispanic or Latino</title>
                  <measurement_list>
                    <measurement group_id="B1" value="4"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Not Hispanic or Latino</title>
                  <measurement_list>
                    <measurement group_id="B1" value="2"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>American Indian or Alaska Native</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Asian</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Native Hawaiian or Other Pacific Islander</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Black or African American</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>White</title>
                  <measurement_list>
                    <measurement group_id="B1" value="6"/>
                  </measurement_list>
                </category>
                <category>
                  <title>More than one race</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Rate of Complete Response to Protocol Therapy</title>
        <description>Complete Response (CR) rate in study participants to protocol therapy. Response will be assessed via CT Scan and bone marrow aspirate/biopsy, if applicable. Complete response criteria include:
Complete disappearance of all detectable clinical and radiographic evidence of disease and disappearance of all disease-related symptoms if present before therapy, and normalization of those biochemical abnormalities definitely assignable to Non Hodgkin's Lymphoma (NHL);
All lymph nodes and tumor masses disappeared or regressed to normal size (≤ 1.5 cm in their greatest transverse diameters for nodes &gt; 1.5 cm before therapy);
Previously involved nodes that were 1.1 to 1.5 cm in their greatest transverse diameter (GTD) before treatment must have decreased to ≤ 1 cm in their GTD after treatment, or by more than 75% bin the sum of the products of the greatest diameters (SPD);
No new sites of disease.</description>
        <time_frame>About 21 days</time_frame>
        <population>Participants who started at least one cycle of protocol therapy.</population>
        <group_list>
          <group group_id="O1">
            <title>Chemotherapy + Antiviral-Based Therapy</title>
            <description>Combination Chemotherapy for up to six (6) 21-day cycles and Antiviral-Based Therapy per study protocol:
Chemotherapy: Up to 6 cycles, 21 days each:
Doxorubicin: 20 mg/m2 intravenously (IV) on Day 1;
Rituximab: 375mg/m2 (optional) IV on Day 1;
Methotrexate: 3.5 gm/m2 IV on Day 2;
Leucovorin: 10 mg/m2 IV starting approximately 24 hours after start of Methotrexate infusion, and then 25 mg orally every 6 hours for at least 10 doses;
Antiviral-Based Therapy
Zidovudine: Starting 750 mg/m2 IV on Day 2, then 1200 mg orally twice daily for 10 doses;
Hydroxyurea: 1,000 mg orally twice daily starting Day 2 for a total of 10 doses.
Doxorubicin: Doxorubicin 20 mg/m2 intravenously will be administered on Day 1 in patients with systemic (non-primary CNS) lymphoma as per institutional guidelines
Methotrexate: Methotrexate administered starting on Day 2.</description>
          </group>
        </group_list>
        <measure>
          <title>Rate of Complete Response to Protocol Therapy</title>
          <description>Complete Response (CR) rate in study participants to protocol therapy. Response will be assessed via CT Scan and bone marrow aspirate/biopsy, if applicable. Complete response criteria include:
Complete disappearance of all detectable clinical and radiographic evidence of disease and disappearance of all disease-related symptoms if present before therapy, and normalization of those biochemical abnormalities definitely assignable to Non Hodgkin's Lymphoma (NHL);
All lymph nodes and tumor masses disappeared or regressed to normal size (≤ 1.5 cm in their greatest transverse diameters for nodes &gt; 1.5 cm before therapy);
Previously involved nodes that were 1.1 to 1.5 cm in their greatest transverse diameter (GTD) before treatment must have decreased to ≤ 1 cm in their GTD after treatment, or by more than 75% bin the sum of the products of the greatest diameters (SPD);
No new sites of disease.</description>
          <population>Participants who started at least one cycle of protocol therapy.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="6"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>One-year Rate of Overall Survival</title>
        <description>Rate of overall survival of study participants at one year since initiation of protocol therapy. Overall survival (OS) will be measured from the date of initiation of study treatment until date of death from any cause. In the absence of death, the follow-up will be censored at date of last contact (censored observation). Kaplan-Meier estimate of overall survival at one-year.</description>
        <time_frame>12 months</time_frame>
        <population>Participants receiving at least one cycle of protocol therapy.</population>
        <group_list>
          <group group_id="O1">
            <title>Chemotherapy + Antiviral-Based Therapy</title>
            <description>Combination Chemotherapy for up to six (6) 21-day cycles and Antiviral-Based Therapy per study protocol:
Chemotherapy: Up to 6 cycles, 21 days each:
Doxorubicin: 20 mg/m2 intravenously (IV) on Day 1;
Rituximab: 375mg/m2 (optional) IV on Day 1;
Methotrexate: 3.5 gm/m2 IV on Day 2;
Leucovorin: 10 mg/m2 IV starting approximately 24 hours after start of Methotrexate infusion, and then 25 mg orally every 6 hours for at least 10 doses;
Antiviral-Based Therapy
Zidovudine: Starting 750 mg/m2 IV on Day 2, then 1200 mg orally twice daily for 10 doses;
Hydroxyurea: 1,000 mg orally twice daily starting Day 2 for a total of 10 doses.
Doxorubicin: Doxorubicin 20 mg/m2 intravenously will be administered on Day 1 in patients with systemic (non-primary CNS) lymphoma as per institutional guidelines
Methotrexate: Methotrexate administered starting on Day 2.</description>
          </group>
        </group_list>
        <measure>
          <title>One-year Rate of Overall Survival</title>
          <description>Rate of overall survival of study participants at one year since initiation of protocol therapy. Overall survival (OS) will be measured from the date of initiation of study treatment until date of death from any cause. In the absence of death, the follow-up will be censored at date of last contact (censored observation). Kaplan-Meier estimate of overall survival at one-year.</description>
          <population>Participants receiving at least one cycle of protocol therapy.</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="6"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="83.3" lower_limit="27.3" upper_limit="97.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>One-Year Rate of Failure-Free Survival (FFS)</title>
        <description>Rate of failure-free survival of study participants one-year after start of protocol therapy. Failure-free survival (FFS) will be measured from the date of treatment initiation until date of documented disease progression, relapse after response, or death from any cause. For patients alive and free of relapse or progression, follow-up time will be censored at the last documented date of failure-free status. Kaplan-Meier estimate of failure-free survival at one-year.</description>
        <time_frame>12 months</time_frame>
        <population>Participants receiving at least one cycle of protocol therapy.</population>
        <group_list>
          <group group_id="O1">
            <title>Chemotherapy + Antiviral-Based Therapy</title>
            <description>Combination Chemotherapy for up to six (6) 21-day cycles and Antiviral-Based Therapy per study protocol:
Chemotherapy: Up to 6 cycles, 21 days each:
Doxorubicin: 20 mg/m2 intravenously (IV) on Day 1;
Rituximab: 375mg/m2 (optional) IV on Day 1;
Methotrexate: 3.5 gm/m2 IV on Day 2;
Leucovorin: 10 mg/m2 IV starting approximately 24 hours after start of Methotrexate infusion, and then 25 mg orally every 6 hours for at least 10 doses;
Antiviral-Based Therapy
Zidovudine: Starting 750 mg/m2 IV on Day 2, then 1200 mg orally twice daily for 10 doses;
Hydroxyurea: 1,000 mg orally twice daily starting Day 2 for a total of 10 doses.
Doxorubicin: Doxorubicin 20 mg/m2 intravenously will be administered on Day 1 in patients with systemic (non-primary CNS) lymphoma as per institutional guidelines
Methotrexate: Methotrexate administered starting on Day 2.</description>
          </group>
        </group_list>
        <measure>
          <title>One-Year Rate of Failure-Free Survival (FFS)</title>
          <description>Rate of failure-free survival of study participants one-year after start of protocol therapy. Failure-free survival (FFS) will be measured from the date of treatment initiation until date of documented disease progression, relapse after response, or death from any cause. For patients alive and free of relapse or progression, follow-up time will be censored at the last documented date of failure-free status. Kaplan-Meier estimate of failure-free survival at one-year.</description>
          <population>Participants receiving at least one cycle of protocol therapy.</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="6"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="37.5" lower_limit="1.1" upper_limit="80.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Rate of Toxicity Related to Protocol Therapy</title>
        <description>Rate of adverse events, serious adverse events or other toxicities related to protocol therapy in study participants.</description>
        <time_frame>Through Duration of Protocol Therapy, Up to six 21-day cycles (+/- 7 days)</time_frame>
        <population>Participants starting at least once cycle of protocol therapy. Participants experiencing toxicity are tabulated by grade (gr.) of toxicity.</population>
        <group_list>
          <group group_id="O1">
            <title>Chemotherapy + Antiviral-Based Therapy</title>
            <description>Combination Chemotherapy for up to six (6) 21-day cycles and Antiviral-Based Therapy per study protocol:
Chemotherapy: Up to 6 cycles, 21 days each:
Doxorubicin: 20 mg/m2 intravenously (IV) on Day 1;
Rituximab: 375mg/m2 (optional) IV on Day 1;
Methotrexate: 3.5 gm/m2 IV on Day 2;
Leucovorin: 10 mg/m2 IV starting approximately 24 hours after start of Methotrexate infusion, and then 25 mg orally every 6 hours for at least 10 doses;
Antiviral-Based Therapy
Zidovudine: Starting 750 mg/m2 IV on Day 2, then 1200 mg orally twice daily for 10 doses;
Hydroxyurea: 1,000 mg orally twice daily starting Day 2 for a total of 10 doses.
Doxorubicin: Doxorubicin 20 mg/m2 intravenously will be administered on Day 1 in patients with systemic (non-primary CNS) lymphoma as per institutional guidelines
Methotrexate: Methotrexate administered starting on Day 2.</description>
          </group>
        </group_list>
        <measure>
          <title>Rate of Toxicity Related to Protocol Therapy</title>
          <description>Rate of adverse events, serious adverse events or other toxicities related to protocol therapy in study participants.</description>
          <population>Participants starting at least once cycle of protocol therapy. Participants experiencing toxicity are tabulated by grade (gr.) of toxicity.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="6"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Patients w/Toxicity Definitely Treatment-Related</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Gr. 4 Toxicity Probably/Possibly Treatment-Related</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Gr. 3 Toxicity Probably/Possibly Treatment-Related</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Gr. 2 Toxicity Probably/Possibly Treatment-Related</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Gr. 1 Toxicity Probably/Possibly Treatment-Related</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>HIV Viral Load in Positive Subjects Before, During and After Protocol Therapy</title>
        <description>Measurement of HIV Viral Load in positive subjects before, during and after protocol therapy to assess the effect of protocol therapy on immune reconstitution or exhaustion.</description>
        <time_frame>From Baseline Up to 1 Year Post-Therapy</time_frame>
        <population>Per protocol, evaluable participants are those who receive 3 or more cycles of treatment. Three of these participants were HIV-positive. Before therapy, HIV viral load was undetectable in 2 participants.</population>
        <group_list>
          <group group_id="O1">
            <title>Chemotherapy + Antiviral-Based Therapy</title>
            <description>Combination Chemotherapy for up to six (6) 21-day cycles and Antiviral-Based Therapy per study protocol:
Chemotherapy: Up to 6 cycles, 21 days each:
Doxorubicin: 20 mg/m2 intravenously (IV) on Day 1;
Rituximab: 375mg/m2 (optional) IV on Day 1;
Methotrexate: 3.5 gm/m2 IV on Day 2;
Leucovorin: 10 mg/m2 IV starting approximately 24 hours after start of Methotrexate infusion, and then 25 mg orally every 6 hours for at least 10 doses;
Antiviral-Based Therapy
Zidovudine: Starting 750 mg/m2 IV on Day 2, then 1200 mg orally twice daily for 10 doses;
Hydroxyurea: 1,000 mg orally twice daily starting Day 2 for a total of 10 doses.
Doxorubicin: Doxorubicin 20 mg/m2 intravenously will be administered on Day 1 in patients with systemic (non-primary CNS) lymphoma as per institutional guidelines
Methotrexate: Methotrexate administered starting on Day 2.</description>
          </group>
        </group_list>
        <measure>
          <title>HIV Viral Load in Positive Subjects Before, During and After Protocol Therapy</title>
          <description>Measurement of HIV Viral Load in positive subjects before, during and after protocol therapy to assess the effect of protocol therapy on immune reconstitution or exhaustion.</description>
          <population>Per protocol, evaluable participants are those who receive 3 or more cycles of treatment. Three of these participants were HIV-positive. Before therapy, HIV viral load was undetectable in 2 participants.</population>
          <units>copies/ml</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="3"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Before Therapy</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="1"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="333"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>During Therapy</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="3"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="NA">HIV viral load undetectable in study participants.</measurement>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>After Therapy</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="3"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="NA">HIV viral load undetectable in study participants.</measurement>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>T-Cell Subset Levels in Peripheral Blood in Positive Participants Before, During and After Protocol Therapy</title>
        <description>Measurement of T-cell subset levels (CD4, CD8) in peripheral blood before, during and after protocol therapy to assess the effect of protocol therapy on immune re-constitution or exhaustion.</description>
        <time_frame>From Baseline Up to 1 Year Post-Therapy</time_frame>
        <population>Per protocol, evaluable participants are those who receive 3 or more cycles of treatment. Three of these participants were HIV-positive. Data for T-cell subset levels (CD4, CD8) were available during and after for two of these three participants.</population>
        <group_list>
          <group group_id="O1">
            <title>Chemotherapy + Antiviral-Based Therapy</title>
            <description>Combination Chemotherapy for up to six (6) 21-day cycles and Antiviral-Based Therapy per study protocol:
Chemotherapy: Up to 6 cycles, 21 days each:
Doxorubicin: 20 mg/m2 intravenously (IV) on Day 1;
Rituximab: 375mg/m2 (optional) IV on Day 1;
Methotrexate: 3.5 gm/m2 IV on Day 2;
Leucovorin: 10 mg/m2 IV starting approximately 24 hours after start of Methotrexate infusion, and then 25 mg orally every 6 hours for at least 10 doses;
Antiviral-Based Therapy
Zidovudine: Starting 750 mg/m2 IV on Day 2, then 1200 mg orally twice daily for 10 doses;
Hydroxyurea: 1,000 mg orally twice daily starting Day 2 for a total of 10 doses.
Doxorubicin: Doxorubicin 20 mg/m2 intravenously will be administered on Day 1 in patients with systemic (non-primary CNS) lymphoma as per institutional guidelines
Methotrexate: Methotrexate administered starting on Day 2.</description>
          </group>
        </group_list>
        <measure>
          <title>T-Cell Subset Levels in Peripheral Blood in Positive Participants Before, During and After Protocol Therapy</title>
          <description>Measurement of T-cell subset levels (CD4, CD8) in peripheral blood before, during and after protocol therapy to assess the effect of protocol therapy on immune re-constitution or exhaustion.</description>
          <population>Per protocol, evaluable participants are those who receive 3 or more cycles of treatment. Three of these participants were HIV-positive. Data for T-cell subset levels (CD4, CD8) were available during and after for two of these three participants.</population>
          <units>cells/mm^3</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="3"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>CD4 count, Before Therapy</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="3"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="328" spread="164.05"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>CD4 count, During Therapy</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="2"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="285" spread="124.58"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>CD4 count, After Therapy</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="2"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="323.5" spread="178.90"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>CD8 count, Before Therapy</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="3"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1246" spread="668.86"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>CD8 count, During Therapy</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="2"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1006" spread="741.05"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>CD8 count, After Thaerapy</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="2"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1006" spread="741.05"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>EBV Viral Load in Peripheral Blood Before, During and After Protocol Therapy</title>
        <description>Measurement of Epstein Barr Virus (EBV) viral load in peripheral blood in study participants before, after treatment, and during surveillance in order to correlate the presence of with tumor load and disease status.</description>
        <time_frame>From Baseline Up to 1 year Post-Therapy</time_frame>
        <population>Serum EBV viral load levels were below the limit of detection in subjects before therapy. Data were not collected during and after therapy.</population>
        <group_list>
          <group group_id="O1">
            <title>Chemotherapy + Antiviral-Based Therapy</title>
            <description>Combination Chemotherapy for up to six (6) 21-day cycles and Antiviral-Based Therapy per study protocol:
Chemotherapy: Up to 6 cycles, 21 days each:
Doxorubicin: 20 mg/m2 intravenously (IV) on Day 1;
Rituximab: 375mg/m2 (optional) IV on Day 1;
Methotrexate: 3.5 gm/m2 IV on Day 2;
Leucovorin: 10 mg/m2 IV starting approximately 24 hours after start of Methotrexate infusion, and then 25 mg orally every 6 hours for at least 10 doses;
Antiviral-Based Therapy
Zidovudine: Starting 750 mg/m2 IV on Day 2, then 1200 mg orally twice daily for 10 doses;
Hydroxyurea: 1,000 mg orally twice daily starting Day 2 for a total of 10 doses.
Doxorubicin: Doxorubicin 20 mg/m2 intravenously will be administered on Day 1 in patients with systemic (non-primary CNS) lymphoma as per institutional guidelines
Methotrexate: Methotrexate administered starting on Day 2.</description>
          </group>
        </group_list>
        <measure>
          <title>EBV Viral Load in Peripheral Blood Before, During and After Protocol Therapy</title>
          <description>Measurement of Epstein Barr Virus (EBV) viral load in peripheral blood in study participants before, after treatment, and during surveillance in order to correlate the presence of with tumor load and disease status.</description>
          <population>Serum EBV viral load levels were below the limit of detection in subjects before therapy. Data were not collected during and after therapy.</population>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>EBV Reactivation in Circulating Peripheral Blood Memory B-cells Before and After Protocol Therapy.</title>
        <description>Measurement of EBV reactivation in circulating peripheral blood memory B-cells before and after treatment with chemotherapy/Zidovudine (ZDV) in order to assess the drug effect on EBV latency.</description>
        <time_frame>From Baseline Up to 1 year Post-Therapy</time_frame>
        <population>This outcome measure was added via amendment for new participants enrolled after December 2016 however; no new participants were enrolled. No data were collected for this outcome measure.</population>
        <group_list>
          <group group_id="O1">
            <title>Chemotherapy + Antiviral-Based Therapy</title>
            <description>Combination Chemotherapy for up to six (6) 21-day cycles and Antiviral-Based Therapy per study protocol:
Chemotherapy: Up to 6 cycles, 21 days each:
Doxorubicin: 20 mg/m2 intravenously (IV) on Day 1;
Rituximab: 375mg/m2 (optional) IV on Day 1;
Methotrexate: 3.5 gm/m2 IV on Day 2;
Leucovorin: 10 mg/m2 IV starting approximately 24 hours after start of Methotrexate infusion, and then 25 mg orally every 6 hours for at least 10 doses;
Antiviral-Based Therapy
Zidovudine: Starting 750 mg/m2 IV on Day 2, then 1200 mg orally twice daily for 10 doses;
Hydroxyurea: 1,000 mg orally twice daily starting Day 2 for a total of 10 doses.
Doxorubicin: Doxorubicin 20 mg/m2 intravenously will be administered on Day 1 in patients with systemic (non-primary CNS) lymphoma as per institutional guidelines
Methotrexate: Methotrexate administered starting on Day 2.</description>
          </group>
        </group_list>
        <measure>
          <title>EBV Reactivation in Circulating Peripheral Blood Memory B-cells Before and After Protocol Therapy.</title>
          <description>Measurement of EBV reactivation in circulating peripheral blood memory B-cells before and after treatment with chemotherapy/Zidovudine (ZDV) in order to assess the drug effect on EBV latency.</description>
          <population>This outcome measure was added via amendment for new participants enrolled after December 2016 however; no new participants were enrolled. No data were collected for this outcome measure.</population>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Baseline Tumor EBV Gene Expression Profile in Study Participants</title>
        <description>Determine baseline tumor EBV gene expression profile to assess viral thymidine kinases. (BXLF1/vTK and BGLF4/PK), EBV latency pattern (I, II or III) and lytic phase.</description>
        <time_frame>Baseline</time_frame>
        <population>This outcome measure was added via amendment for new participants enrolled after December 2016 however; no new participants were enrolled. No data were collected for this outcome measure.</population>
        <group_list>
          <group group_id="O1">
            <title>Chemotherapy + Antiviral-Based Therapy</title>
            <description>Combination Chemotherapy for up to six (6) 21-day cycles and Antiviral-Based Therapy per study protocol:
Chemotherapy: Up to 6 cycles, 21 days each:
Doxorubicin: 20 mg/m2 intravenously (IV) on Day 1;
Rituximab: 375mg/m2 (optional) IV on Day 1;
Methotrexate: 3.5 gm/m2 IV on Day 2;
Leucovorin: 10 mg/m2 IV starting approximately 24 hours after start of Methotrexate infusion, and then 25 mg orally every 6 hours for at least 10 doses;
Antiviral-Based Therapy
Zidovudine: Starting 750 mg/m2 IV on Day 2, then 1200 mg orally twice daily for 10 doses;
Hydroxyurea: 1,000 mg orally twice daily starting Day 2 for a total of 10 doses.
Doxorubicin: Doxorubicin 20 mg/m2 intravenously will be administered on Day 1 in patients with systemic (non-primary CNS) lymphoma as per institutional guidelines
Methotrexate: Methotrexate administered starting on Day 2.</description>
          </group>
        </group_list>
        <measure>
          <title>Baseline Tumor EBV Gene Expression Profile in Study Participants</title>
          <description>Determine baseline tumor EBV gene expression profile to assess viral thymidine kinases. (BXLF1/vTK and BGLF4/PK), EBV latency pattern (I, II or III) and lytic phase.</description>
          <population>This outcome measure was added via amendment for new participants enrolled after December 2016 however; no new participants were enrolled. No data were collected for this outcome measure.</population>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Measurement of Immune Activation Markers and Inflammation in Peripheral Blood</title>
        <description>Measurement of immune activation markers and inflammation in peripheral blood in response to treatment and EBV reactivation.</description>
        <time_frame>Through Duration of Response to Protocol Therapy Until Disease Progression, Up to 5 years</time_frame>
        <population>This outcome measure was added via amendment for new participants enrolled after December 2016 however; no new participants were enrolled. No data were collected for this outcome measure.</population>
        <group_list>
          <group group_id="O1">
            <title>Chemotherapy + Antiviral-Based Therapy</title>
            <description>Combination Chemotherapy for up to six (6) 21-day cycles and Antiviral-Based Therapy per study protocol:
Chemotherapy: Up to 6 cycles, 21 days each:
Doxorubicin: 20 mg/m2 intravenously (IV) on Day 1;
Rituximab: 375mg/m2 (optional) IV on Day 1;
Methotrexate: 3.5 gm/m2 IV on Day 2;
Leucovorin: 10 mg/m2 IV starting approximately 24 hours after start of Methotrexate infusion, and then 25 mg orally every 6 hours for at least 10 doses;
Antiviral-Based Therapy
Zidovudine: Starting 750 mg/m2 IV on Day 2, then 1200 mg orally twice daily for 10 doses;
Hydroxyurea: 1,000 mg orally twice daily starting Day 2 for a total of 10 doses.
Doxorubicin: Doxorubicin 20 mg/m2 intravenously will be administered on Day 1 in patients with systemic (non-primary CNS) lymphoma as per institutional guidelines
Methotrexate: Methotrexate administered starting on Day 2.</description>
          </group>
        </group_list>
        <measure>
          <title>Measurement of Immune Activation Markers and Inflammation in Peripheral Blood</title>
          <description>Measurement of immune activation markers and inflammation in peripheral blood in response to treatment and EBV reactivation.</description>
          <population>This outcome measure was added via amendment for new participants enrolled after December 2016 however; no new participants were enrolled. No data were collected for this outcome measure.</population>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>4 years</time_frame>
      <group_list>
        <group group_id="E1">
          <title>Chemotherapy + Antiviral-Based Therapy</title>
          <description>Combination Chemotherapy for up to six (6) 21-day cycles and Antiviral-Based Therapy per study protocol:
Chemotherapy: Up to 6 cycles, 21 days each:
Doxorubicin: 20 mg/m2 intravenously (IV) on Day 1;
Rituximab: 375mg/m2 (optional) IV on Day 1;
Methotrexate: 3.5 gm/m2 IV on Day 2;
Leucovorin: 10 mg/m2 IV starting approximately 24 hours after start of Methotrexate infusion, and then 25 mg orally every 6 hours for at least 10 doses;
Antiviral-Based Therapy
Zidovudine: Starting 750 mg/m2 IV on Day 2, then 1200 mg orally twice daily for 10 doses;
Hydroxyurea: 1,000 mg orally twice daily starting Day 2 for a total of 10 doses.
Doxorubicin: Doxorubicin 20 mg/m2 intravenously will be administered on Day 1 in patients with systemic (non-primary CNS) lymphoma as per institutional guidelines
Methotrexate: Methotrexate administered starting on Day 2.</description>
        </group>
      </group_list>
      <serious_events>
        <default_vocab>CTCAE (4.0)</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="6"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="6"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>Febrile Neutropenia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="6"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Investigations</title>
            <event_list>
              <event>
                <sub_title>Platelet count decreased</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="6"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>Dehydration</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="6"/>
              </event>
              <event>
                <sub_title>Hypophosphatemia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="6"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Hypoxia</sub_title>
                <counts group_id="E1" events="2" subjects_affected="1" subjects_at_risk="6"/>
              </event>
              <event>
                <sub_title>Pneumonitis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="6"/>
              </event>
              <event>
                <sub_title>Adult respiratory distress syndrome</sub_title>
                <counts group_id="E1" events="2" subjects_affected="1" subjects_at_risk="6"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <default_vocab>CTCAE (4.0)</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="6" subjects_at_risk="6"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>Anemia</sub_title>
                <counts group_id="E1" events="23" subjects_affected="6" subjects_at_risk="6"/>
              </event>
              <event>
                <sub_title>Leukocytes</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="6"/>
              </event>
              <event>
                <sub_title>Leukocytosis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="6"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Palpitations</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="6"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Abdominal Pain</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="6"/>
              </event>
              <event>
                <sub_title>Constipation</sub_title>
                <counts group_id="E1" events="2" subjects_affected="1" subjects_at_risk="6"/>
              </event>
              <event>
                <sub_title>Diarrhea</sub_title>
                <counts group_id="E1" events="4" subjects_affected="2" subjects_at_risk="6"/>
              </event>
              <event>
                <sub_title>Dyspepsia</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="6"/>
              </event>
              <event>
                <sub_title>Gastritis</sub_title>
                <counts group_id="E1" events="3" subjects_affected="1" subjects_at_risk="6"/>
              </event>
              <event>
                <sub_title>Gastroesophageal reflux disease</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="6"/>
              </event>
              <event>
                <sub_title>Mucositis oral</sub_title>
                <counts group_id="E1" events="12" subjects_affected="3" subjects_at_risk="6"/>
              </event>
              <event>
                <sub_title>Nausea</sub_title>
                <counts group_id="E1" events="16" subjects_affected="5" subjects_at_risk="6"/>
              </event>
              <event>
                <sub_title>Vomiting</sub_title>
                <counts group_id="E1" events="7" subjects_affected="3" subjects_at_risk="6"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Edema limbs</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="6"/>
              </event>
              <event>
                <sub_title>Fatigue</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="6"/>
              </event>
              <event>
                <sub_title>Fever</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="6"/>
              </event>
              <event>
                <sub_title>Headache</sub_title>
                <counts group_id="E1" events="4" subjects_affected="2" subjects_at_risk="6"/>
              </event>
              <event>
                <sub_title>Insomnia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="6"/>
              </event>
              <event>
                <sub_title>Malaise</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="6"/>
              </event>
              <event>
                <sub_title>Oral pain</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="6"/>
              </event>
              <event>
                <sub_title>Pharyngolaryngeal pain</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="6"/>
              </event>
              <event>
                <sub_title>Weight loss</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="6"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Conjunctivitis infective</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="6"/>
              </event>
              <event>
                <sub_title>Genital Herpes</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="6"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Investigations</title>
            <event_list>
              <event>
                <sub_title>Blood bilirubin increased</sub_title>
                <counts group_id="E1" events="4" subjects_affected="1" subjects_at_risk="6"/>
              </event>
              <event>
                <sub_title>Creatinine increased</sub_title>
                <counts group_id="E1" events="6" subjects_affected="2" subjects_at_risk="6"/>
              </event>
              <event>
                <sub_title>INR increased</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="6"/>
              </event>
              <event>
                <sub_title>Lymphocyte count decreased</sub_title>
                <counts group_id="E1" events="12" subjects_affected="3" subjects_at_risk="6"/>
              </event>
              <event>
                <sub_title>Neutrophil count decreased</sub_title>
                <counts group_id="E1" events="5" subjects_affected="2" subjects_at_risk="6"/>
              </event>
              <event>
                <sub_title>White blood cell decreased</sub_title>
                <counts group_id="E1" events="13" subjects_affected="4" subjects_at_risk="6"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>Alanine aminotransferase increased</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="6"/>
              </event>
              <event>
                <sub_title>Anorexia</sub_title>
                <counts group_id="E1" events="4" subjects_affected="3" subjects_at_risk="6"/>
              </event>
              <event>
                <sub_title>Aspartate aminotransferase increased</sub_title>
                <counts group_id="E1" events="5" subjects_affected="2" subjects_at_risk="6"/>
              </event>
              <event>
                <sub_title>Hypercalcemia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="6"/>
              </event>
              <event>
                <sub_title>Hyperglycemia</sub_title>
                <counts group_id="E1" events="47" subjects_affected="6" subjects_at_risk="6"/>
              </event>
              <event>
                <sub_title>Hyperkalemia</sub_title>
                <counts group_id="E1" events="2" subjects_affected="1" subjects_at_risk="6"/>
              </event>
              <event>
                <sub_title>Hypernatremia</sub_title>
                <counts group_id="E1" events="4" subjects_affected="3" subjects_at_risk="6"/>
              </event>
              <event>
                <sub_title>Hypoalbuminemia</sub_title>
                <counts group_id="E1" events="9" subjects_affected="3" subjects_at_risk="6"/>
              </event>
              <event>
                <sub_title>Hypocalcemia</sub_title>
                <counts group_id="E1" events="10" subjects_affected="4" subjects_at_risk="6"/>
              </event>
              <event>
                <sub_title>Hypoglycemia</sub_title>
                <counts group_id="E1" events="4" subjects_affected="2" subjects_at_risk="6"/>
              </event>
              <event>
                <sub_title>Hypokalemia</sub_title>
                <counts group_id="E1" events="18" subjects_affected="4" subjects_at_risk="6"/>
              </event>
              <event>
                <sub_title>Hypomagnesemia</sub_title>
                <counts group_id="E1" events="3" subjects_affected="1" subjects_at_risk="6"/>
              </event>
              <event>
                <sub_title>Hyponatremia</sub_title>
                <counts group_id="E1" events="6" subjects_affected="3" subjects_at_risk="6"/>
              </event>
              <event>
                <sub_title>Hypophosphatemia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="6"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Back pain</sub_title>
                <counts group_id="E1" events="4" subjects_affected="2" subjects_at_risk="6"/>
              </event>
              <event>
                <sub_title>Joint effusion</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="6"/>
              </event>
              <event>
                <sub_title>Pain in extremity</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="6"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Depressed level of consciousness</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="6"/>
              </event>
              <event>
                <sub_title>Peripheral sensory neuropathy</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="6"/>
              </event>
              <event>
                <sub_title>Personality change</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="6"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Psychiatric disorders</title>
            <event_list>
              <event>
                <sub_title>Anxiety</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="6"/>
              </event>
              <event>
                <sub_title>Insomnia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="6"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Reproductive system and breast disorders</title>
            <event_list>
              <event>
                <sub_title>Hiccups</sub_title>
                <counts group_id="E1" events="6" subjects_affected="3" subjects_at_risk="6"/>
              </event>
              <event>
                <sub_title>Hypoxia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="6"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Cough</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="6"/>
              </event>
              <event>
                <sub_title>Dyspnea</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="6"/>
              </event>
              <event>
                <sub_title>Epistaxis</sub_title>
                <counts group_id="E1" events="3" subjects_affected="1" subjects_at_risk="6"/>
              </event>
              <event>
                <sub_title>Pleural effusion</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="6"/>
              </event>
              <event>
                <sub_title>Pneumonitis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="6"/>
              </event>
              <event>
                <sub_title>Sore throat</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="6"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Flushing</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="6"/>
              </event>
              <event>
                <sub_title>Hyperhidrosis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="6"/>
              </event>
              <event>
                <sub_title>Pruritus</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="6"/>
              </event>
              <event>
                <sub_title>Seborrheic Dermatitis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="6"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>Hypotension</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="6"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>All Principal Investigators ARE employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Juan C. Ramos MD</name_or_title>
      <organization>University of Miami</organization>
      <phone>305-243-1326</phone>
      <email>jramos2@med.miami.edu</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

